Last reviewed · How we verify
sIPV vaccine /DTaP vaccine
sIPV vaccine /DTaP vaccine is a vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of diphtheria, Prevention of tetanus.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against poliovirus (sIPV component) and diphtheria, tetanus, and pertussis toxins (DTaP component).
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against poliovirus (sIPV component) and diphtheria, tetanus, and pertussis toxins (DTaP component). Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of diphtheria, Prevention of tetanus.
At a glance
| Generic name | sIPV vaccine /DTaP vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The sIPV (sequential inactivated poliovirus vaccine) component contains inactivated poliovirus types 1, 2, and 3 that trigger humoral and cellular immune responses. The DTaP component contains diphtheria and tetanus toxoids (inactivated bacterial toxins) and acellular pertussis antigens, which similarly induce protective antibody responses against these three bacterial pathogens. Together, the combination vaccine provides immunological protection against five vaccine-preventable diseases.
Approved indications
- Prevention of poliomyelitis (poliovirus types 1, 2, and 3)
- Prevention of diphtheria
- Prevention of tetanus
- Prevention of pertussis (whooping cough)
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Immunogenicity of After Primary Immunization and Booster Immunization of sIPV
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR (PHASE4)
- Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA (PHASE4)
- Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV vaccine /DTaP vaccine CI brief — competitive landscape report
- sIPV vaccine /DTaP vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about sIPV vaccine /DTaP vaccine
What is sIPV vaccine /DTaP vaccine?
How does sIPV vaccine /DTaP vaccine work?
What is sIPV vaccine /DTaP vaccine used for?
Who makes sIPV vaccine /DTaP vaccine?
What drug class is sIPV vaccine /DTaP vaccine in?
What development phase is sIPV vaccine /DTaP vaccine in?
What are the side effects of sIPV vaccine /DTaP vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of poliomyelitis (poliovirus types 1, 2, and 3)
- Indication: Drugs for Prevention of diphtheria
- Indication: Drugs for Prevention of tetanus
- Compare: sIPV vaccine /DTaP vaccine vs similar drugs
- Pricing: sIPV vaccine /DTaP vaccine cost, discount & access